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Summary
CUTL1, also known as CDP, Cut, or Cux-1, is a homeodomain transcriptional regulator known to be involved in develop-
ment and cell cycle progression. Here we report that CUTL1 activity is associated with increased migration and invasive-
ness in numerous tumor cell lines, both in vitro and in vivo. Furthermore, we identify CUTL1 as a transcriptional target of
transforming growth factor β and a mediator of its promigratory effects. CUTL1 activates a transcriptional program regu-
lating genes involved in cell motility, invasion, and extracellular matrix composition. CUTL1 expression is significantly
increased in high-grade carcinomas and is inversely correlated with survival in breast cancer. This suggests that CUTL1
plays a central role in coordinating a gene expression program associated with cell motility and tumor progression.S I G N I F I C A N C E
The ability to migrate and invade into surrounding tissues, blood, and lymphatic vessels is one of the hallmarks of cancer and a
prerequisite for local tumor progression and metastatic spread. However, the underlying mechanisms controlling cell invasiveness
remain poorly understood. TGFβ is known as one of the key factors modulating cell migration, invasion, and tumor progression. In
this study, we identify CUTL1, a transcription factor involved in development and cell differentiation, as a major regulator of cell
motility and invasion and an important downstream effector of TGFβ. The fact that CUTL1 expression is increased in high-grade
carcinomas and inversely correlated with survival in breast cancer underlines its important role in tumor progression.Introduction
CUTL1, also known as CDP (CCAAT displacement protein),
Cut, or Cux-1, belongs to a family of homeobox transcription
factors involved in the regulation of cell growth and differentia-
tion (Nepveu, 2001). It is evolutionarily conserved and contains
four DNA binding domains, three of which are known as Cut
repeats and one as a Cut homeodomain (Harada et al., 1995).
CUTL1 has been described as a transcriptional activator as
well as a transcriptional repressor. Its activity has been associ-
ated with cellular proliferation and cell cycle progression (Van
Wijnen et al., 1996; Coqueret et al., 1998; Truscott et al., 2003),
as well as modulation of genes involved in terminal differentia-
tion (van Gurp et al., 1999; Skalnik et al., 1991). Knockout
studies with the murine homolog, Cux-1, revealed reduced
growth, retarded differentiation of the lung epithelia, hair follicle
defects, reduced male fertility, and deficient T and B cell func-
tion (Ellis et al., 2001; Luong et al., 2002; Sinclair et al., 2001).
In contrast, mice transgenic for Cux-1 showed organomegaly
and multiorgan hyperplasia (Ledford et al., 2002).CANCER CELL : JUNE 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INC.CUTL1 has been demonstrated to be a phosphorylation
target of several kinases that modulate its DNA binding affinity:
phosphorylations by cyclin A-cdk1 and by PKC at various sites
have been shown to inhibit DNA binding activity (Coqueret et
al., 1996; Santaguida et al., 2001). No reports exist so far on
the transcriptional regulation of CUTL1 in mammalian cells.
Studies in flies indicate that the Drosophila homolog of CUTL1,
Cut, is a major determinant of cell type specification down-
stream of the notch pathway (Tavares et al., 2000) and may
also interact with the wingless (Wg) signaling pathway (Mic-
chelli et al., 1997).
The role of CUTL1 in tumorigenesis and tumor progression
remains to be elucidated. Although initial databases on loss
of heterozygosity studies suggested that CUTL1 might be a
candidate tumor suppressor gene (Zeng et al., 1999), a recent
report suggests instead that CUTL1 could play a role in pro-
moting breast cancer: Goulet et al. describe a tissue-specific
CUTL1 isoform that appears to be strongly expressed in some
breast tumors and, when overexpressed, inhibits tubule forma-
tion of breast cancer cells in vitro (Goulet et al., 2002).DOI 10.1016/j.ccr.2005.05.018 521
A R T I C L ENumerous signaling pathways have been implicated in the
regulation of tumor progression and cell invasion. TGFβ is
known to be a major modulator of tumor cell migration (Mas-
sague, 1998), invasiveness (Seton-Rogers et al., 2004), and ep-
ithelial-mesenchymal transition (EMT) (Grunert et al., 2003). In
addition to the canonical Smad-mediated signaling pathway,
TGFβ also activates other pathways involving mitogen-acti-
vated protein kinases (MAPK), including JNKs and p38MAPK
(Yu et al., 2002).
We have identified CUTL1 in a high-throughput screen for
modulators of cell motility using an RNA interference library-
based approach (O.E.P. and J.D., unpublished data). In this as-
say, CUTL1 was discovered as a potential positive regulator of
cell motility. Based on these results, we aimed to characterize
the role of CUTL1 in the control of cell migration, invasiveness,
and tumor progression. Here we demonstrate that CUTL1
strongly promotes cell motility and invasiveness in a variety of
cell systems in vitro and in vivo. In addition, we investigated
the effects of tumor-related signaling pathways on the tran-
scriptional activity of CUTL1. We could show that CUTL1 is a
transcriptional target of TGFβ, thereby mediating promigratory
effects of TGFβ. The important role of CUTL1 in promoting cell
motility and invasiveness is underlined by the fact that CUTL1
expression is strongly associated with a less differentiated phe-
notype in breast and pancreatic carcinomas and with de-
creased patient survival in invasive breast cancer.
Results
Generation of cell lines stably expressing
CUTL1 RNAi vector
CUTL1 was identified in a high throughput RNA interference
screen for genes that influence cell motility. This screen utilized
the Netherlands Cancer Institute RNA interference library,
which targets 8,000 human genes (Berns et al., 2004), and will
be described in detail elsewhere (O.E.P. and J.D., unpublished
data). Briefly, three RNA interference vectors against each gene
were cotransfected together with a GFP expression construct
into highly motile carcinoma cells. One gene was analyzed per
transfected well. After two days, fluorescent cells were iden-
tified and tracked by time-lapse video microscopy for a further
day. Cells expressing CUTL1 RNAi vectors showed signifi-
cantly decreased motility.
In order to study the biological role of endogenous CUTL1,
we stably suppressed CUTL1 expression by vector-based
transfection of specific short hairpin RNA (shRNA) in NIH3T3
fibroblasts, which express high endogenous CUTL1 levels and
are known to be highly motile. A number of clones that showed
no detectable CUTL1 expression (Figure 1A) were used for fur-
ther studies. Expression differences of nuclear CUTL1 could
also be confirmed by immunocytochemistry (Figure 1B). Inter-
estingly, diminished CUTL1 expression was associated with a
strikingly altered cell morphology. CUTL1 RNAi clones were in-
creased in cell size and appeared to be less spindle-shaped
compared to control clones a with normal fibroblast-like phe-
notype (Figure 1C). The increase in cell size was confirmed by
various FACS-based assays, including forward scatter, fluores-
cein diacetate staining, and FITC staining (data not shown).
CUTL1 enhances migration and invasion
To examine the effects of CUTL1 on cell motility and migration,
we employed three different tissue culture assays examining522Figure 1. Generation of NIH3T3 cell lines stably expressing CUTL1 RNAi
A: Western blot with anti-CDP (Santa Cruz) showing two representative
NIH3T3 clones stably transfected with shRNA for mCUTL1 as compared to
control (empty vector only) cells.
B: Immunocytochemical detection of nuclear CUTL1 in NIH3T3 control and
CUTL1 RNAi cells, as determined by immunostaining with anti-CDP (Santa
Cruz). Bars represent 10 m.
C: Morphological appearance of subconfluent and confluent NIH3T3 con-
trol and CUTL1 shRNA cells, as shown by phase-contrast microscopy. Bars
represent 50 m.various aspects of migratory behavior. First, directed migration
into an artificial “wound” was measured in a confluent mono-
layer culture of NIH3T3 cells with or without endogenous
CUTL1 expression (control versus CUTL1 RNAi). Control cells
extensively migrated into the wound area within 8 hr, but this
was significantly reduced in CUTL1 RNAi cells (Figures 2A and
2B). Similar results were also obtained by using two-chamberCANCER CELL : JUNE 2005
A R T I C L EFigure 2. CUTL1 enhances migration and in-
vasion
A:Wound healing assay with NIH3T3 control and
CUTL1 RNAi cells. Bar represent 200 m.
B: Quantification of cells migrated into a de-
fined wound area after 8 hr. Cells in 4 defined
areas per group per experiment were quanti-
fied. Data are representative for three indepen-
dent experiments and are shown as mean ±
SEM. *p < 0.05 as compared to control cells.
C:Quantification of the two-chamber migration
assay of NIH3T3 control and stable CUTL1 shRNA
cells. Fixed and stained cells on the bottom side
of an 8 m pore membrane were counted as
migrated cells/2 mm2. Data are representative
for three independent experiments and are
shown as mean ± SEM. *p < 0.05 as compared
to control cells.
D: Video time-lapse microscopy of NIH3T3 con-
trol and stable CUTL1 shRNA cells. At least 48
cells per condition per experiment were
tracked. Data are presented as bar and whisker
graphs, showing the median and the distribu-
tion of 50% (bar) and 90% (whisker) of all
tracked cells, and are representative of three
independent experiments. *p < 0.05 as com-
pared to control cells.
E: Video time-lapse microscopy of HT1080, U87-
MG, MDA-MB-231, and NIH3T3 cells with (RNAi)
or without (C) transient suppression of CUTL1 by
siRNA (oligonucleotides hCUTL1/I for human
cells or mCUTL1 for NIH3T3 cells). Data are pre-
sented as bar and whisker graphs, and are re-
presentative of three independent experiments.
*p < 0.05 as compared to control cells.
F: Quantification of two-chamber migration as-
say with HT080, U87-MG, MDA-MB-436, and
PANC1 cells transiently transfected with control
and CUTL1 siRNA (oligonucleotide hCUTL1/I).
Fixed and stained cells on the bottom side of an
8 m pore membrane were counted as mi-
grated cells/2 mm2. Data are representative for
three independent experiments and are shown
as mean ± SEM. *p < 0.05 as compared to con-
trol cells.
G: Representative phalloidin staining for actin
cytoskeleton in NIH3T3 cells stably transfected
with CUTL1 shRNA and MDA-MB-231 cells with or
without transient suppression of CUTL1 by siRNA
(oligonucleotide hCUTL1/I). Sites of adhesion
sites are indicated by arrows. Bars represent
10 m.
H: Two-chamber invasion assay of HT1080, U87-MG, MDA-MB-436, and PANC1 cells with or without transient suppression of CUTL1 by siRNA (oligonucleotide
hCUTL1/I). Invaded cells in 4 fields per group were counted. Data are representative of three independent experiments. *p < 0.05 as compared to
control cells.migration assays in which cells migrated through a membrane
with 8 m pores from serum-free medium toward 10% FCS-
containing medium. In the CUTL1 RNAi clones, the proportion
of migrated cells was significantly reduced (Figure 2C).
Knockdown of CUTL1 also slightly reduced cell proliferation,
but to a much lesser extent than its effects on migration (see
Supplemental Figure S1). To rule out a bias due to differences
in proliferation, we also tracked single cells by video time-lapse
microscopy, whereby we could confirm that CUTL1 RNAi cells
displayed significantly lower motility (Figure 2D). For represen-
tative time-lapse video, see Supplemental Videos.
To demonstrate that these observations are not specific for
fibroblasts or for a single CUTL1 RNA interference sequence,CANCER CELL : JUNE 2005we performed video time-lapse microscopy and two-chamber
migration assays on a variety of different cell lines after tran-
sient transfection of synthetic siRNA oligonucleotides target-
ing different regions of CUTL1 to the shRNA vector. First, we
could demonstrate that with this transient approach, we could
achieve a marked reduction of CUTL1 protein levels in all cell
lines used (see Supplemental Figure S2). Various cell lines of
different origin, such as fibrosarcoma (HT1080), glioblastoma
(U87-MG), and breast cancer (MDA-MB-231) cells all showed
significantly reduced motility when endogenous CUTL1 was
suppressed, as assayed by time-lapse microscopy (Figure 2E).
This was also confirmed by two-chamber migration assays for
a variety of cell lines of mesenchymal and epithelial origin, in-523
A R T I C L Ecluding PANC1 pancreatic carcinoma cells (Figure 2F). To de-
monstrate that the observed effect was not an off-target effect
of one particular siRNA oligonucleotide, we confirmed that two
different oligonucleotides targeting different regions of the
CUTL1 mRNA were able to decrease CUTL1 expression paral-
leled by a decreased migration in HT1080 cells (see Supple-
mental Figure S3). Furthermore, the suppression of CUTL1 led
to a marked actin reorganization and a decrease in focal adhe-
sions and membrane protrusions associated with cell motility,
as assayed by phalloidin staining, in both NIH3T3 fibroblasts
and MDA-MB-231 epithelial cells (Figure 2G and Supplemental
Figure S4). The decreased number of focal adhesions in
NIH3T3 cells was confirmed by a decrease in vinculin-positive
adhesion sites (see Supplemental Figure S5).
To examine whether CUTL1 also affects invasiveness involv-
ing movement through a three-dimensional matrix, we per-
formed in vitro invasion assays with several invasive cell lines,
including MDA-MB-231 breast cancer and PANC1 pancreatic
cancer cells. Invasion through a membrane with 8 m pores
coated with a 30 m layer of Matrigel consisting of extracellular
matrix proteins was significantly reduced by over 30% in either
cell line when endogenous CUTL1 was transiently suppressed
by siRNA transfection (Figure 2H).
To confirm these results implicating CUTL1 in invasiveness
in vivo, we generated stable CUTL1 knockdown clones by
shRNA vector introduction into the invasive cell lines HT1080
fibrosarcoma, MDA-MB-436 breast carcinoma, and PANC1
pancreatic carcinoma, resulting in a significant reduction of
CUTL1 expression in each cell line (Figures 3A and 3B and
data not shown). Tail vein injection of two clones each with or
without endogenous CUTL1 knockdown into nude mice re-
sulted in a significant reduction of pulmonary metastatic colo-
nizations, both in number and size (Figures 3C–3E and data
not shown). It is therefore likely that CUTL1 expression may
be important in establishing a transcriptional program that is
conducive to metastatic behavior of cells in vivo.
CUTL1 is transcriptionally upregulated by TGFβ
Given the major role of TGFβ in regulating migration and inva-
siveness, we were interested in whether TGFβ influences
CUTL1 activity. We found that CUTL1 is transcriptionally
upregulated by TGFβ in numerous cell lines such as NIH3T3
fibroblasts, AML12 hepatocytes, HT1080 fibrosarcoma, MDA-
MB-231 and MDA-MB-436 breast cancer, HCT116 colon can-
cer, and PANC1 pancreatic cancer cells (Figures 4A and 4D
and data not shown). This TGFβ effect was mediated via
TGFβRI, since SB431542, an inhibitor of ALK4/5/7 (Inman et
al., 2002), was able to abolish TGFβ-induced upregulation of
CUTL1, as confirmed in NIH3T3 cells (Figure 4B), MDA-MB-
231 cells, and PANC1 cells (data not shown). A weaker in-
duction of CUTL1 expression on serum treatment was not
SB431542-sensitive, suggesting that TGFβ-independent path-
ways also affect CUTL1 transcription. CUTL1 mRNA induction
by TGFβ appeared 4 hr after addition of TGFβ, suggesting that
CUTL1 is not one of the early response genes of TGFβ (Figure
4C). To investigate the pathways acting downstream of TGFβ
in CUTL1 upregulation, we used clones of the mouse hepato-
cyte cell line AML12 in which the expression of Smad4 had
been stably suppressed by shRNA (A.R.R. and J.D., unpub-
lished data) as well as MDA-MB-436 breast cancer cells with
or without transient suppression of Smad4 by siRNA. AML12524Figure 3. CUTL1 enhances pulmonary colonization in vivo
A: Western blot with anti-GST-CUTL1 showing two representative HT1080
clones each stably transfected with shRNA for hCUTL1 as compared to
control (empty vector only) cells.
B: Western blot with anti-GST-CUTL1 showing two representative MDA-MB-
436 clones each stably transfected with shRNA for hCUTL1 as compared
to control (empty vector only) cells.
C: Representative H&E staining for pulmonary colonizations with HT1080
control and CUTL RNAi cells 17 days after tail vein injections into nu/nu
mice. Pulmonary colonies are marked with an arrow. Bars represent
100 m.
D:Quantification of the pulmonary colonizations with stable HT1080 control
and CUTL1 shRNA cells 17 days after tail vein injection into nu/nu mice.
Data are presented as mean number of colonies per animal, as assayed
in serial H&E sections of the lungs (15 sections at a distance of 150 m from
each other), and are representative for 2 CUTL1 RNAi clones and 2 con-
trol clones each. *p = 0.05 as compared to control cells. Data shown are
mean ± SEM.
E: Quantification of the pulmonary colonizations with stable MDA-MB-436
control and CUTL1 shRNA cells 40 days after tail vein injection into nu/nu
mice. Data are presented as mean number of colonies per animal, as
assayed in serial H&E sections of the lungs (15 sections at a distance of 150
m from each other), and are representative for 2 CUTL1 RNAi clones and
2 control clones each. *p = 0.05 as compared to control cells. Data shown
are mean ± SEM.cells lacking Smad4 showed significantly lower CUTL1 protein
levels than wild-type cells (Figure 4D), as did MDA-MB-436
cells with transient Smad4 suppression (see Supplemental
Figure S6) and PANC1 cells (data not shown), indicating
that Smad4-dependent signaling is involved in the transcrip-
tional regulation of CUTL1. In addition, coincubation with theCANCER CELL : JUNE 2005
A R T I C L EFigure 4. TGFβ induces CUTL1 expression via Smad4 and p38MAPK
A: TGFβ increases CUTL1 expression at mRNA (4 hr) and protein level (10
hr) in NIH3T3 cells grown in the presence or absence of serum. RT-PCR was
performed using mCUTL1 specific primers, and Western blot was per-
formed with rabbit anti-CDP antibody (Santa Cruz).
B: The TGFβ receptor type I inhibitor SB431542 decreases TGFβ-induced
CUTL1 induction, as assessed by real-time PCR. NIH3T3 cells preincubated
with or without SB431542 (10 M) for 30 min were stimulated with TGFβ (10
ng/ml) under serum-free conditions or with 10% FCS for additional 4 hr.
Data are shown as CUTL1 mRNA expression relative to unstimulated control
and are representative for three independent experiments. Data shown
are mean ± SEM.
C: Time course of TGFβ-induced CUTL1 expression under serum-free condi-
tions, as assessed by real-time PCR. Data are shown as CUTL1 expression
relative to unstimulated control and are representative for three indepen-
dent experiments. Data shown are mean ± SEM.
D: Western blot of CUTL1 transcriptional regulation by TGFβ and p38MAPK
inhibitor SB202190 in AML12 hepatocytes with or without stable suppression
of SMAD4 by shRNA. Anti-CDP antibody (Santa Cruz) was used. Cells were
grown in 10% fetal calf serum.CANCER CELL : JUNE 2005p38MAPK inhibitor SB202190 resulted in additional downregu-
lation of both basal and TGFβ-induced CUTL1 levels (Figure
4D and Supplemental Figure S6), indicating that p38MAPK-
dependent signaling, known to be an additional effector path-
way downstream of TGFβ, also plays a role in modulating
CUTL1 levels.
CUTL1 is required for TGFβ effects on migration
To test the biological significance of the TGFβ-induced upregu-
lation of CUTL1, we examined the influence of CUTL1 on mi-
gration in the presence or absence of TGFβ. Addition of TGFβ
significantly increased the migration of NIH3T3 control cells,
paralleled by an increase in CUTL1 levels. In contrast, in stable
CUTL1 RNAi NIH 3T3 cells, the effect of TGFβ on the basal mi-
gration rate was absent (Figure 5A). These results were confirmed
by two-chamber migration assays (Figure 5B) and wound healing
assays (Figure 5C). Furthermore, transient transfection of
HT1080 fibrosarcoma cells with CUTL1 siRNA confirmed that
both basal and TGFβ-induced migration strongly correlate with
the level of CUTL1 expression (Figure 5D), which was also ob-
served in MDA-MB-231 breast cancer cells (data not shown).
Based on these data, it appears likely that CUTL1 expression is
required for TGFβ to exert its promigratory effects. To examine
whether CUTL1 mediates TGFβ-induced epithelial-mesenchy-
mal transition (EMT), thereby enhancing cell migration, we used
EpH4 and Ha-Ras-transformed EpH4 (EpRas) mammary epi-
thelial cells before and after TGFβ-induced EMT (EpRasXT cells),
a cell system which has been described as a model system for
EMT (Jechlinger et al., 2003). However, despite decreasing cell
motility as confirmed by Boyden chamber assays, CUTL1
knockdown did not in any way alter the expression levels of
any of the marker proteins associated with EMT, such as E
cadherin, vimentin, or cytokeratin 8/18 (data not shown).
Therefore, CUTL1 seems to mediate promigratory effects of
TGFβ independently of EMT and does not appear to play a role
in the regulation of EMT.
Transcriptional effects of CUTL1 knockdown
To determine the transcriptional program regulated by CUTL1
that might underlie the differences seen in cell motility and in-
vasion, we performed Affymetrix microarray gene expression
profiling experiments with two NIH3T3 CUTL1 RNAi clones and
two control clones.
Using highly stringent significance criteria, we generated
lists containing genes which were more highly expressed in
control relative to CUTL1 RNAi cells (Table 1, Upregulated by
CUTL1) or more highly expressed in CUTL1 RNAi relative to
control cells (Table 2, Downregulated by CUTL1). The genes
were grouped into several categories by their ontological clas-
sification using the MAPPFinder software and the available lit-
erature.
The group of upregulated genes mainly consists of genes
related to embryonic development and differentiation, genes
involved in adhesion and cell motility, genes encoding secreted
extracellular matrix proteins, and genes encoding various tran-
scription factors and enhancers of protein synthesis (Table 1).
Many of these have previously been described as modulators
of cell invasion in various tumor cell models (see Discussion).
The group of downregulated genes (Table 2) consists mainly
of genes associated with inflammatory reaction, acute-phase
response, and chemotaxis, as well as genes encoding secreted525
A R T I C L EFigure 5. CUTL1 mediates TGFβ effects on migration and invasion
A: Video time-lapse microscopy of NIH3T3 control and stable CUTL1 shRNA
cells ± TGFβ. Data are presented as bar and whisker graphs and are repre-
sentative of three independent experiments. *p < 0.05 as compared to
CUTL1 shRNA cells. **p < 0.05 as compared to control cells. In parallel,
CUTL1 expression in cells under each condition was determined by West-
ern blot (lower panel). 10% donor calf serum containing medium was used.
B: Quantification of the two-chamber migration assay of stable NIH3T3526marker. To further corroborate our data with another epithelial
control and CUTL1 shRNA cells ± TGFβ. Fixed and stained cells on the bot-
tom side of the membrane were counted and quantified as migrated
cells/2 mm2. Data are representative for three independent experiments
and are shown as mean ± SEM. *p < 0.05 as compared to CUTL RNAi cells.
C: Wound healing assay with stable NIH3T3 control and CUTL1 shRNA
cells ± TGFβ. Cells in 4 defined areas per group per experiment were quan-
tified. Data are representative for three independent experiments and are
shown as mean ± SEM. *: p < 0.05 as compared to CUTL1 RNAi cells.
**: p < 0.05 as compared to control cells.
D: Video time-lapse microscopy of HT1080 cells with or without transiently
suppressed CUTL1 by siRNA (oligonucleotide hCUTL1/I) ± TGFβ. Data are
representative of three independent experiments. Simultaneously, cells
were treated identically and harvested for Western blot in order to analyze
CUTL1 expression (lower panel). Experiments were performed in serum con-
taining medium.extracellular matrix proteins. We could confirm the microarray
data for the vast majority of the genes tested, both on RNA
(see Supplemental Figure S7) and protein levels (see Supple-
mental Figure S8) as well as on promoter level for selected
genes (see Supplemental Figure S9). To demonstrate that the
identified target genes are not specific for NIH3T3, we per-
formed additional experiments using real-time PCR after tran-
sient knockdown of CUTL1 in various cancer cell lines. We
could confirm that several CUTL1 target genes identified by
the microarray experiments, such as WNT5A, were also regu-
lated by CUTL1 in fibrosarcoma and breast and pancreatic
cancer cells (see Supplemental Figure S10).
Taken together, these microarray results suggest that CUTL1
predominantly regulates genes involved in migration, invasion,
adhesion, and modulation of the extracellular matrix, indicating
that it might be involved in the control of cell motility in vitro
and invasiveness in tumors.
CUTL1 expression is increased in high-grade breast
and pancreatic cancers
As reduction in CUTL1 expression leads to reduced motility
and invasiveness of cell lines from several tissue origins both
in vitro and in vivo, we sought to elucidate the physiological
relevance of CUTL1 in tumor progression and metastasis by
studying CUTL1 expression in 138 patients with invasive ductal
carcinoma of the breast where full histopathological data and
active clinical followup up to 22 years were available. This co-
hort was analyzed for known prognostic markers (estrogen re-
ceptor, progesterone receptor, tumor size, lymph node status,
histological grade) and showed trends in overall and relapse-
free survival in keeping with the expected outcome. For de-
tailed patient characteristics, see Supplemental Table S1. In
situ hybridization on multiple tissue core arrays showed CUTL1
expression in more than half of the tumors. Interestingly, poorly
differentiated high-grade (G3) breast carcinomas expressed
significantly more CUTL1 than well-differentiated low-grade
(G1) tumors (Figures 6A and 6B). This correlation was con-
firmed in an independent series of 35 breast cancer tissues
by immunohistochemistry, demonstrating higher expression of
CUTL1 protein in G2 and G3 tumors as compared to G1 tu-
mors (Figures 6C and 6D). Furthermore, in patients with high-
grade (G3) tumors, CUTL1 expression, as assessed by ISH,
inversely correlated with relapse-free survival (Figure 6E) and
overall survival (see Supplemental Figure S11) as a prognosticCANCER CELL : JUNE 2005
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Annotation Ratio CUTL/RNAi Gene symbol Full name
Development/differentiation
Mm.103593 49.7 DKK2 dickkopf-2
Mm.3063 8.1 PTN pleiotrophin
Mm.8180 3.9 DPYSL3 dihydropyrimidinase-LIKE 3
Mm.32207 2.4 WNT5A wingless-type mmtv integration site, member 5a
Mm.29205 2.3 BRUNOL4 bruno-like 4
Mm.89924 2.1 MRPPLF3 mitogen-regulated protein proliferin-3
Mm.139314 2.1 DPPA5 developmental pluripotency associated-5
Mm.9336 2.1 GNB4 guanine nucleotide-binding protein, beta-4 subunit
Adhesion/motility
Mm.29798 5.0 CD34 hematopoietic progenitor cell antigen cd34
Mm.2877 4.7 ALCAM activated leukocyte cell adhesion molecule
Mm.225096 3.3 ITGA6 integrin, alpha-6
Mm.16749 2.9 KLRA18 killer cell lectin-like receptor a18
Mm.154610 2.7 TM4SF10 transmembrane 4 superfamily, member10
Mm.1 2.0 S100A10 100 calcium binding protein a10 (calpactin)
Extracellular matrix
Mm.25755 3.5 ASPN asporin
Mm.234850 2.6 COL3A1 collagen, type iii, alpha-1
Mm.205021 2.4 NPNT nephronectin
Mm.5020 2.4 SEMA3A semaphorin 3a
Mm.738 2.1 COL4A1 collagen, type iv, alpha-1
Transcription/translation
Mm.5025 3.8 ETV4 ets variant gene 4
Mm.9845 3.5 RPS27 ribosomal protein s27
Mm.479 2.9 MYBL1 v-myb myeloblastosis oncogene homolog-like 1
Mm.18810 2.8 ZFP422 zinc finger protein 422
Mm.45039 2.1 LRRFIP1 leucine-rich repeat in flii-interacting protein 1
Mm.925 2.0 TFDP1 transcription factor dp1
Others
Mm.246318 2.5 EIG180 ethanol-inducble gene 180
Mm.62886 2.0 GALNT7 udp-n-acetyl-a-d-galactosamine:polypeptide n
Mm.29357 14.3 1300017C10RIK acetylgalacto saminyltransferase 7
Mm.29690 3.0 4930415K17RIK
Mm.25307 2.3 2810470D21RIK
Mm.259140 2.2 A230070D14RIK
Mm.259998 2.2 C730016P09RIK
Mm.214959 2.2 BB128963
Mm.38488 2.1 AI256840cancer, we performed immunohistochemistry with a multiple
tissue array containing 25 pancreatic cancer tissues with de-
fined grade. These pancreatic cancer tissues also showed a
stronger CUTL1 protein staining in high histological grade
(G2/3) tumors compared to low grade (G1) tumors (see Supple-
mental Figures S12 and S13). These data on RNA and protein
levels strongly indicate that elevated levels of CUTL1 expres-
sion may play an important role in enhancing invasiveness and
tumor progression in breast and pancreatic cancer.
Discussion
The ability to migrate and invade through the basement mem-
brane into surrounding tissues, blood, and lymphatic vessels
is one of the essential hallmarks of cancer and a prerequisite
for local tumor progression and metastatic spread. In an RNAi-
library-based high-throughput screen for regulators of cell mo-
tility (O.E.P. and J.D., unpublished data), we identified CUTL1
as a potential modulator of cell migration. Based on these find-CANCER CELL : JUNE 2005ings, we examined the role of CUTL1 in the regulation of cell
motility and invasiveness. In summary, we found that depletion
of CUTL1 from various cell types results in reduction in cell
motility and invasiveness, both in vitro and in vivo. CUTL1 is
required for the expression of a number of cell surface and
other proteins involved in the control of cell adhesion and mi-
gration. In addition, TGFβ treatment increases CUTL1 expres-
sion, which is required for short-term effects of TGFβ on cell
motility. CUTL1 expression is found to correlate with increased
histological grade and poor prognosis in breast cancer.
Our hypothesis, based on the RNAi high-throughput screen,
that CUTL1 plays a role in the regulation of cell motility could
be confirmed experimentally by migration and invasion assays
in a number of systems in vitro and in vivo. CUTL1 expression
is required for efficient migration of both epithelial and mes-
enchymal cells on a two-dimensional surface in vitro and for
optimal invasion through a three-dimensional gel of extracellu-
lar matrix. In addition, reduction in CUTL1 expression severely
impaired the ability of tumor cells to form lung colonies in an527
A R T I C L ETable 2. Genes downregulated by CUTL1
Annotation Ratio CUTL/RNAi Gene symbol Full name
Inflammatory response/chemotaxis
Mm.26730 0.04 HP haptoglobin
Mm.465 0.09 CXCL12 chemokine (c-x-c motif) ligand 12
Mm.14277 0.29 SAA3 serum amyloid a 3
Mm.15534 0.36 IL1A interleukin 1 alpha
Mm.27001 0.48 E430037F08Rik Riken cdna e430037f08 gene
Extracellular matrix
Mm.214514 0.01 PRELP proline arginine-rich repeat/leucine-rich repeat
Mm.22650 0.05 SERPINA3N serine proteinase inhibitor, clade a, member 3n
Mm.38274 0.06 CHI3L1 chitinase 3-like 1
Mm.18888 0.07 LUM lumican
Mm.41573 0.09 FMOD fibromodulin
Mm.102752 0.40 C1GALT1 core 1 udp-gal:acetylgal.-1,3-galactosyltransferase
Mm.18087 0.44 LGALS9 lectin, galactose binding, soluble 9
Others
Mm.27061 0.16 RIKEN cDNA 0610011I04 GENE
Mm.28385 0.23 RIKEN cDNA 1810009M01 GENEexperimental metastasis model in vivo. This assay measures
several crucial aspects of the metastatic process, such as the
ability of single cancer cells to adhere, survive, and proliferate
in a different organ context. Some other prerequisites of metas-
tasis, such as the ability of cells to enter the circulation through
a basement membrane, however, are not addressed by the
pulmonary colonization assay. Overall, we suggest that high
levels of CUTL1 expression are associated with the increased
motility typical of invasive carcinoma cells, in contrast to the
normally relatively nonmotile untransformed epithelial cells.
Since TGFβ is known to be a major modulator of cell migra-
tion and invasion (Massague, 1998; Lehmann et al., 2000), we
tested its effect on CUTL1 expression, finding that CUTL1 is
transcriptionally induced following TGFβ treatment. We there-
fore propose that CUTL1 might be a significant new pathway
through which TGFβ exerts its promigratory and proinvasive
effects. These effects of TGFβ fall into two classes: short-term
changes, occurring in a few hours (Seton-Rogers et al., 2004),
and long-term changes, requiring altered differentiation of the
cell through epithelial-mesenchymal transition (Grunert et al.,
2003). CUTL1 does not appear to play a role in the regulation
of EMT, but is required for the short-term effects of TGFβ on
cell motility, involving both SMAD4-dependent and p38 MAPK-
dependent pathways. Initial analysis of the murine CUTL1 pro-
moter suggests the presence of a putative SMAD binding site
within 2 kilobases upstream of the transcriptional start site.
However, since this site is not consistently conserved among
mammalian species, its physiological significance remains to
be elucidated. Further investigation will be required to deter-
mine the exact mechanism whereby CUTL1 gene expression
is controlled by TGFβ.
By using multiple tissue core arrays, we could demonstrate
the pathophysiological significance of CUTL1 expression in
breast and pancreatic cancer. The increased expression of
CUTL1 in high-grade breast and pancreatic cancers and its
inverse correlation with overall and relapse-free survival of pa-
tients with breast cancer suggests that CUTL1 transcriptional
activity has a major impact on tumor progression. The probe
used for in situ hybridization will recognize mRNA encoding528full-length CUTL1 protein (p200), from which a shorter, more
active form (p110) is generated by proteolytic processing. A
still shorter version of CUTL1 (p75) is made from an mRNA
transcribed from an alternative initiation site within intron 20,
but this would not be recognized by the in situ hybridization
probe used here (Goulet et al., 2002). CUTL1 p75 has more
stable DNA binding activity and has been shown to disrupt tu-
bule formation in collagen by T47D breast carcinoma cells
when overexpressed.
Recently, cathepsin cysteine proteases have been described
as being important effectors of invasive growth and angiogen-
esis during multistage tumorigenesis. Several different cathep-
sins were found to be expressed at increased levels in various
cell types involved in tumor progression in the RIP-Tag2 mouse
model of pancreatic islet cell carcinogenesis, including cathep-
sin L, which was expressed exclusively in the tumor cells
(Joyce et al., 2004). An isoform of cathepsin L lacking a signal
peptide localizes to the nucleus in S phase and has been re-
ported recently to process CUTL1 p200 to the more transcrip-
tionally active p110 form (Goulet et al., 2004). It is possible that
increased cathepsin L expression in tumor cells synergizes
with elevated CUTL1 levels by promoting its posttranslational
processing and activation, leading to elevated expression of
CUTL1 target genes involved in tumor cell invasion of sur-
rounding tissue.
We investigated the identity of genes whose expression is
regulated by CUTL1 by the combined use of RNA interference
technology and microarray expression profiling. Transcriptional
profiling after suppression of endogenous CUTL1 expression
by shRNA avoids potential biases introduced by overexpres-
sion techniques, thus probably providing a more physiologi-
cally relevant global expression profile. The gene expression
profile observed is likely to be specific for knockdown of
CUTL1: we did not observe significant upregulation of in-
terferon-response genes (Bridge et al., 2003), described as
nonspecific side effects induced by some siRNAs, and we had
no indication of major off-target effects of the RNA sequence
used for generating the stable RNAi clones. While these se-
quences did not have any perfect matches other than CUTL1CANCER CELL : JUNE 2005
A R T I C L EFigure 6. CUTL1 is highly expressed in high-grade
breast cancer and correlates with grading and
survival
A: In situ hybridization with hCUTL1 probe of 1
normal breast tissue and 3 representative breast
cancer tissues with different histopathological
grades and increasing levels of CUTL1 RNA. On
the right, hCUTL1-positive areas are revealed
as autoradiographic silver grains in dark-field
images; on the left, the same specimens are
shown by Giemsa staining. Bars represent
200 m.
B: CUTL1 mRNA expression levels in grade 1 (G1)
and grade 3 (G3) breast cancers. CUTL1 expres-
sion was scored as negative (0), or positive
(three levels: +, ++, +++). Proportion of tumors
with the respective score out of 138 examined
tissues is given. Significance was calculated by
nonparametric permutation testing.
C: Immunohistochemistry using the rabbit anti-
GST-CUTL antibody of 1 normal breast tissue and
3 representative breast cancer tissues with dif-
ferent histopathological grades and increasing
protein levels of CUTL1. Bars represent 100 m.
D: CUTL1 protein expression levels in grade 1
(G1) and grade 2/3 (G2/3) breast cancers.
CUTL1 expression was scored as negative (0) or
positive (three levels: +, ++, +++). Proportion of
tumors with the respective score out of 35 ex-
amined tissues is given. Significance was calcu-
lated by nonparametric permutation testing.
E: Inverse association of CUTL1 RNA expression
with relapse-free survival in grade 3 ductal
breast cancers. Breast tissue carcinomas were
grouped as CUTL1-negative or CUTL1-positive,
as assessed by ISH, and correlated with the clin-
ical followup of the 68 patients examined. Data
are presented as Kaplan-Meier curve and signi-
ficance was determined using χ2 testing.in the relevant mammalian genomes, genes showing partial
matches (13–15/19) to the RNAi sequence by BLAST search
did not show any suppression of expression in the microarray
experiments.
Many of the CUTL1 upregulated target genes identified by
the microarray analysis have previously been described as
modulators of cell invasion in various tumor cell models:
among others, pleiotrophin (PTN), a secreted heparin binding
growth factor, induces growth and metastasis in mesenchymal
cells (Chauhan et al., 1993) and is rate-limiting for glioblastoma
growth (Powers et al., 2002). WNT5A, a member of the wing-
less gene family, has been associated with motility and inva-
sion of metastatic melanoma (Weeraratna et al., 2002). AL-
CAM, a member of the immunoglobulin superfamily, enhances
growth and migration (van Kempen et al., 2000). S100A10
functions as a plasminogen receptor and has been shown to
enhance invasiveness of colorectal cancer cells (Zhang et al.,
2004). Perhaps most significantly, α6 integrin (ITGA6) is ex-
pressed considerably more strongly in the presence of CUTL1:
this integrin, particularly in combination with β4, has been im-CANCER CELL : JUNE 2005plicated in the progression of several tumor types, including
breast cancer (Friedrichs et al., 1995; Guo and Giancotti,
2004). Reduced α6 integrin expression could lead to reduced
adhesiveness on laminin extracellular matrix and hence re-
duced invasiveness. In addition, among the genes negatively
regulated by CUTL1 were several proteoglycans, downregula-
tion of which has been associated with poor outcome in inva-
sive breast cancer (Troup et al., 2003).
The data presented here demonstrate that the transcription
factor CUTL1 plays a critical role in establishing a pattern of
gene expression that favors cancer cell motility and invasive
behavior. CUTL1 expression is induced by TGFβ and is re-
quired for TGFβ promotion of cell motility. If the technical prob-
lems inherent in targeting transcription factors could be over-
come, CUTL1 could represent a novel target for the blocking
of tumor invasion.
Experimental procedures
Plasmids and siRNA
Myc-tagged full-length human CUTL1 in pMX, as well as CUTL1 nt 831–
1336, in pXJ42 were kind gifts from A. Nepveu. The shRNA for mouse and529
A R T I C L Ehuman CUTL1 (5#-AAGAAGAACACTCCAGAGGATTT-3#) was cloned as
hairpin oligonucleotide into pSuper.retro.puro (Oligoengine, Seattle, WA) ac-
cording to the manufacturer’s instructions, and stable clones were obtained
after selection with puromycin. The shRNA for mouse SMAD4 was cloned
into pSuper (A.R.R., unpublished data) and cotransfected with pBabe.puro
for puromycin selection. Control clones were obtained after transfecting the
empty vectors.
The reporter plasmids for WNT5A, DAB2, and PTN were generated by
PCR amplification of the 2 kb upstream the transcriptional start site and
cloning of the 2 kb DNA fragments into the KpnI/BglII sites of pGL3-
Enhancer (Promega, Madison, WI). The DNA polymerase α-pGL3-basic-Luc
(−1517/+45) was a kind gift from A. Nepveu (Truscott et al., 2003), and the
CD34 454-SCL-pXSH-Luc construct was a kind gift from D. Krause (Krause
et al., 1997).
For transient transfection of CUTL1 siRNA, the following sense se-
quences were used (purchased from Ambion, Austin, TX): hCUTL1/I 5#-
GGAACAGAAGUUACAGAAUtt-3#, hCUTL1/II 5#-GGAAGCUGAAGCAGCU
UUCtt-3#, mCUTL1: 5#-GGUUCUGGAAUAACUCUUUtt-3#. For transient
transfection of hSMAD4 siRNA, the following sense sequence was used:
hSMAD4 5#-GGUGGAGAGAGUGAAACAUtt-3#. 140 pmole siRNA/well was
transfected using Effectene or Transmessenger (Qiagen, Hilden, Germany)
as transfection agent in 6-well plates. As negative control, the Silencer
Negative Control siRNA from Ambion was used. In the motility assays, cells
were transfected with siRNA twice, with an interval of 24 hr. Three hours
after the second transfection, the cells were split sparsely for migration, and
another three hours later, the tracking experiment was started for 24 hr.
Materials and cell lines
Puromycin (2.5 g/ml) was obtained from Sigma. The p38MAPK inhibitor
SB202190 (10 M) was from Calbiochem, and rhTGFβ (10 ng/ml) was from
R&D systems. ALK4/5/7 inhibitor SB431542 was a kind gift from C. Hill,
London. All cell lines were obtained from ATCC.
Multiple tissue core arrays
The human breast carcinoma tissues were obtained from the tissue bank
at Cancer Research UK Breast Pathology Laboratory at Guy’s Hospital,
London. All human tissues were used with approval of the local research
ethics committee. Multiple tissue core arrays were produced from represen-
tative tumor areas from donor blocks of cases from the Guy’s unit and
validated as described for in situ hybridization (Gillett et al., 2000). Each
case had been previously assessed for tumor size, lymph node status,
estrogen, and progesterone receptor status. For detailed characteristics of
the cases used see, Supplemental Table S1. Grading was determined by
using the modified Bloom & Richardson system (Elston and Ellis, 1991).
As independent data sets for immunohistochemical studies, commercially
available breast and pancreatic cancer tissue core arrays (Petagen Inc.,
Seoul, Korea) were used. The breast array contained 4 nonneoplastic breast
tissues and 50 carcinoma tissues, among them 35 with defined histological
grade (Bloom & Richardson system). The pancreatic array contained 4 non-
neoplastic pancreas tissues and 33 carcinoma tissues, among them 25 with
defined histological grade which were used for the correlation with CUTL
expression. The statistical analyses were calculated using the statistical
package S-Plus.
Flow cytometry
FACS analysis was performed as described previously (Michl et al., 2003).
For fluorescein diacetate staining (Elliott et al., 2003), cells were resus-
pended in 1 ml PBS at 106 per ml, and 10 l of fluorescein diacetate (1 g/
ml) was added to the cells for 10 min. For FITC staining (Crissman and
Steinkamp, 1973), cells were resuspended in 1 ml PBS containing 5 l FITC
(1 g/ml), 20 l propidium iodide (2 mg/ml), and 50 l RNase (100 g/ml)
for 30 min.
Microarray analysis
Experiments using Affymetrix GeneChip Mouse Genome 430A 2.0 Array
oligonucleotide arrays were performed following the manufacturer’s recom-
mendation (http://www.affymetrix.com/support/technical/manual/expression_
manual.affx). A complete description of all procedures and statistical analy-
sis is available in the MIAME checklist file in the Supplemental Data. Anno-
tation and classification of the genes was performed using MAPPFinder530(http://www.genmapp.org/MAPPFinder.html). Significantly regulated genes
are presented with the ratio between the mean expression values of two
CUTL1 expressing clones and two CUTL1 shRNA knockdown clones each
in duplicate experiments (4 data points per group).
RT-PCR
Reverse transcription was performed using the Superscript first strand syn-
thesis kit (Invitrogen). PCR was performed for 30 cycles. Quantitative real-
time PCR analyses using the comparative CT method were performed on
an ABI PRISM 7700 Sequence Detector System using the SYBR Green
PCR Master Mix kit (Perkin Elmer, Applied Biosystems, Wellesley, MA, USA)
according to the manufacturer’s instructions. Following initial incubation at
50°C for 2 min and 10 min at 95°C, amplification was performed for 40
cycles at 95°C for 15 s and 60°C for 1 min. Specific primer pairs were
determined with the PrimerExpress program (Applied Biosystems). The hu-
man cyclophilin A gene (RefSeq ID NM_021130) was used as the internal
standard. Primer sequences are available on request.
Western blotting
5 × 105 cells were lysed in HEPES buffer containing 1% Triton X-100, soni-
cated, size-fractionated by SDS-PAGE on precast gels (NuPAGE, Invitro-
gen), and blotted onto PVDF membranes (Millipore, Watford, UK). The fol-
lowing antibodies were used for immunodetection: rabbit anti-CDP (Santa
Cruz, Santa Cruz, CA), our own rabbit anti-CUTL1 (antigen: GST-hCUTL1
nt2551-3451), goat anti-actin (Santa Cruz), rabbit anti-DAB2 (Santa Cruz),
mouse anti-N-cadherin (Zymed, San Francisco, CA), rabbit anti-lumican
(kind gift of T. Ishiwata, Tokyo), mouse anti-ALCAM (Antigenix America,
Huntington Station, NY), rabbit anti-mouse SDF1A/CXCL12 (Peprotech,
London, UK), mouse Annexin II light chain/S100A10 (BD Transduction
Laboratories), goat anti-SEMA3A (Santa Cruz), rabbit anti-IL1A (Abcam).
Following peroxidase-coupled secondary antiserum (Amersham Pharmacia,
Little Chalfont, UK), blots were detected by ECL chemiluminescence (Am-
ersham).
Luciferase reporter assays
Cells were transiently transfected using GeneJuice (Merck Biosciences,
Nottingham, UK) according to the manufacturer’s instructions, and har-
vested 24 hr after transfection. Because the internal control plasmid is itself
often repressed by CDP/Cux, as a control for transfection efficiency, the
purified β-galactosidase protein (Sigma) was included in the transfection
mix, as previously described (Truscott et al., 2003; Howcroft et al., 1997).
The luciferase assays were performed using the Luciferase Assay System
(Promega, Madison, WI), and β-galactosidase activity was detected using
2-Nitrophenyl β-D-galactopyranoside (ONPG, Sigma, Poole, UK) in sub-
strate buffer (1 mM MgCl2, 1 mg/ml ONPG, 75 mM sodium phosphate
buffer [pH 7.4], 60 mM β-mercaptoethanol) at 420 nm.
Wound healing assays
An artificial “wound” was created using a 10 l pipette tip on confluent cell
monolayers in 6-well culture plates in serum-containing medium. Pho-
tographs were taken at 0 and 8 hr. Quantitative analysis of the wound clo-
sure was calculated by counting the number of cells per 105 m2 wound
area at 8 hr.
Two-chamber migration and invasion assays
Cell invasion was determined by using the modified two-chamber migration
assay (8 m pore size, BD Biosciences) or invasion assay (membrane
coated with a layer of Matrigel extracellular matrix proteins) according to
the manufacturer’s instructions. 2.5 × 104 cells were seeded in serum-free
medium into the upper chamber and migrated/invaded toward 10% FCS
as a chemoattractant in the lower chamber for 6 hr (HT1080 cells) or 18 hr
(all other cell lines). Cells in the upper chamber were carefully removed
using cotton buds and cells at the bottom of the membrane were fixed and
stained with crystal violet 0.2%/methanol 20%. Quantification was per-
formed by counting the stained cells.
Video time-lapse microscopy
Time-lapse imaging of migrating cells was performed on an inverted Zeiss
Axiovert 135TV microscope (X-Y-Z motorized stage/piezo Z control; Zeiss,CANCER CELL : JUNE 2005
A R T I C L EJena, Germany) over 24 hr in serum-containing medium at 37°C/10% CO2.
Images were obtained with a Hamamatsu Orca ER firewire CCD camera
every 7 or 20 min, and analyzed using image analysis software (AQM Ad-
vance6 and Tracker, Kinetic Imaging Ltd, Bromborough, UK). Migration of
each cell was analyzed by measuring the distance traveled by a cell nucleus
over the 24 hr time period. Statistical analysis was performed using the
Mathematica 4.2 software (Wolfram Research, Long Hanborough, UK). The
average migration speed in m/min was calculated by analyzing at least 24
cells/group.
MTT proliferation assay
The cell proliferation kit (MTT, Roche Diagnostics, Mannheim, Germany)
was performed in 96-well format according to the manufacturer’s instruc-
tions.
In vivo metastasis assay
Female NMRI nu/nu mice were injected with 106 HT1080, MDA-MB-436, or
PANC1 cells/0.1 ml PBS into the tail vein. 6 mice per group were injected,
and 2 clones each of cells stably transfected with CUTL shRNA/pRetro-
super or pRetrosuper vector only were used. 17 (HT1080) or 40 (PANC1,
MDA-MB-436) days after injection, mice were sacrificed and serial sections
of the lungs, cut at a distance of 150 m from each other, were H&E stained.
The number of pulmonary colonies was counted in 15 sections per lung.
In situ hybridization
CUTL1 mRNA levels were studied using in situ hybridization (ISH) as de-
scribed previously (Poulsom et al., 1998). The human CUTL1 probe (nt 330–
1040) was PCR-amplified and cloned into the KpnI and SphI sites of the
pGEM3Z vector (Promega). Expression within the tumor epithelium was
scored independently in a blinded manner as negative, weak, moderate, or
strong. The surrounding tissue stroma showed weak expression of CUTL1.
B-actin mRNA was detected on a near serial section as a positive control
for each tissue section.
Immunocytochemistry and immunohistochemistry
Cells grown on a coverslip were fixed in 3% paraformaldehyde, incubated
with 0.1% Triton X-100, microwaved for antigen retrieval, blocked with 1%
BSA, and stained with rabbit anti-CDP (Santa Cruz). As secondary antibody,
biotin- or TRITC-labeled anti-rabbit IgG was used. For actin cytoskeleton
staining, cells were incubated with Alexa488-conjugated phalloidin (Molec-
ular Probes) according to the manufacturer’s protocol. For vinculin staining,
a mouse vinculin antibody (Sigma) was used and detected by Cy3-labeled
anti mouse-IgG (Dianova, Hamburg). Analysis was performed using a laser
scanning confocal microscope (Zeiss Axioplan 2 Upright). Immunohisto-
chemical analysis was performed as previously described (Wagner et al.,
2003). In short, paraffin sections were stained after antigen retrieval (micro-
wave in antigen unmasking solution, Vector Laboratories, Burlingame, CA)
with rabbit anti-GST-CUTL1 (1:200). Antibody binding was visualized using
a biotinylated secondary antibody, avidine conjugated peroxidase (ABC
method; Vector Laboratories), and 3,3#diaminobenzidine tetrachloride
(DAB) as a substrate, and hematoxylin as counterstain.
Supplemental data
Supplemental data for this article can be found at http://www.cancercell.
org/cgi/content/full/7/6/521/DC1/.
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